Helsinn Group and Glenmark Pharmaceuticals enter into an exclusive licensing agreement for launch of AKYNZEO® in India and Nepal 4 April 2018
Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced 28 March 2018
Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards 26 March 2018
1 Helsinn Group Announces First Patient Enrolled in Phase 3b Study of NEPA IV vs NEPA Oral for the prevention of chemotherapy induced nausea and vomiting (CINV) in Women with Breast Cancer 20 March 2018
Helsinn Group announces the appointment of Paul Rittman as Chief Executive Officer, Helsinn Therapeutics (HTU) 28 February 2018
US Court of Appeals for Federal Circuit Rejects Petition by Helsinn for Rehearing En Banc of Federal Circuit Panel Ruling That Certain Patents Covering Aloxi® in the US Market Are Invalid 18 January 2018
Helsinn Group and MEI Pharma Announce that Pracinostat has Received Orphan Drug Designation from the European Medicines Agency for the Treatment of acute myeloid leukemia (AML) 12 January 2018
A call for action to patient entrepreneurs in the area of cancer to compete at the Lyfebulb-Helsinn Summit for the first ever Lyfebulb- Helsinn Innovation Award 9 January 2018
Helsinn to honor Anna Braglia Endowed Young Investigator Award recipient at Helsinn reception during JP Morgan Healthcare Conference 2018 8 January 2018
Linkedin